Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | BMC Cancer

Fig. 2

From: Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST

Fig. 2

a Patient with a pelvic mass for whom RECIST is an adequate measure of tumor burden, and volumetric measurement provides little additional information. At the most recent follow-up appointment, RECIST indicated a partial response (–43.9 %) and volume indicated a minor response (–59.9 %). b Volumetric measurement of the patient’s primary lesion. c Six months later, the tumor had shrunk by both RECIST and volume

Back to article page